anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Compositions and methods for reducing the risk of skin cancer. The novel compositions include at least one effective protease inhibitor. Preferred protease inhibitors include serine protease inhibitors and metallo- protease inhibitors. The protease inhibitors are preferably included in concentrations ranging from approximately 10 picograms to 10 milligrams per milliliter of the skin-applicable topical mixtures. The topical mixtures preferably include a suitable topical vehicle such as a cream, lotion, or ointment. One class of anti-carcinogenic skin treatment compositions of this invention preferably includes the desired protease inhibitors in combination with a suitable sunscreen agent or agents, such as para-amino benzoic acid, to provide particularly advantageous compositions for reducing the risk of sunlight-induced skin cancer.
The invention relates to a vaccine, preferably for human use, against IgE-mediated allergic reactions. The vaccine contains a protein having the entire amino acid sequence of the constant CH2-CH3 domains of the epsilon chain of the IgE molecule or a structurally stable unit of said amino acid sequence, the protein optionally being coupled to one or more heterologous carrier proteins, and optionally containing an adjuvant. The vaccine is injected, with or without adjuvant, to raise the concentration of endogenous anti-IgE antibodies in the plasma of allergy subjects. In practice, the vaccine can be used against all types of IgE-mediated allergies since the antibodies are not dependent of the antigen specificity of the IgE molecule but will reduce the total IgE pool of the subject. Therefore, the vaccine is aimed at being used for treatment of subjects having different types of IgE-mediated allergies. The increased concentrations of anti-IgE antibodies reduces the free pool of antigen-specific IgE, which thereby strongly reduces the risk for an allergen-mediated release of the physiologically highly active substances which are stored or produced in connection with granula release from mast cells and basophilic leucocytes.
PROBLEM TO BE SOLVED: To obtain a new compound having phosphodiesterase inhibiting action and useful as a physiologically active substance for antiasthmatic agent, bronchodilator, antiallergic agent, antiinflammatory agent, antirheumatic agent, etc. SOLUTION: This pysiologically active substance NA23063 analog is represented by formula I [R1 to R5 are each same or different H, OH, OR (R groups are same groups selected from a 1-4C alkyl, a 1-4C alkylcarbonyl, etc.); X is 0 or direct bond; excluding the case that R1 , R3 , R4 and R6 are each OH, R2 and R5 are each H and X is direct bond] or its pharmacologically allowable salt, e.g. NA23063A of formula II. The NA23063A has the following physical and chemical properties; appearance, yellow powder; molecular weight, 538; molecular formula, C3 OH18 O10 ; solubility, soluble in lower alcohols, acetone, ethyl acetate and dimethylsulfoxide and insoluble in hexane, petroleum ether and water; etc.  The physiologically active substance can be separated from a cultivation product obtained by culturing a microorganism belonging to the genus Streptomyces and capable of producing the physiologically active substance.
Pre-surgery scans, surgical resection and post-surgery follow-up. All patients will receive a fluorodeoxyglucose (FDG)-PET scan as part of standard of care. This scan must be completed within 28 days of surgery for the patient to be eligible. All patients will be offered the opportunity to receive an additional 18F-FMISO-PET scan, until 18 such scans are administered. Prior to surgery, patients will be administered a single dose of 0.5 g/m\^2 (approximately 13 mg/kg) of oral Hypoxyprobe™-1 (pimonidazole, HCl).
PURPOSE: In a relatively large cohort of thalassemia intermedia (TI) patients, we systematically investigated myocardial iron overload (MIO), function, and replacement fibrosis using cardiac magnetic resonance (CMR), we assessed the clinical determinants of global heart T2* values, and we explored the association between multiparametric CMR findings and cardiac complications.
MATERIALS AND METHODS: We considered 254 beta-TI patients (43.14 ± 13.69 years, 138 females) consecutively enrolled in the Extension-Myocardial Iron Overload in Thalassemia project. MIO was quantified by T2* technique and biventricular function and atrial areas by cine images. Macroscopic myocardial fibrosis was detected by late gadolinium enhancement technique.
RESULTS: Compared to never/sporadically transfused patients, regularly transfused (RT)-TI patients exhibited significantly lower global heart T2* values, biventricular end-diastolic volume indexes, left ventricular mass index, and cardiac index. In RT-TI patients, age and serum ferritin levels were the strongest predictors of global heart T2* values. Independently from the transfusional state, cardiac T2* values were not associated with biventricular function. Of the 103 (40.6%) patients in whom the contrast medium was administrated, 27 (26.2%) had replacement myocardial fibrosis. Age, sex distribution, cardiac iron, and biventricular function parameters were comparable between patients without and without replacement myocardial fibrosis. Twenty-five (9.8%) patients had a history of cardiac complications (heart failure and arrhythmias). Increased age and replacement myocardial fibrosis emerged as significant risk markers for cardiac complications.
CONCLUSIONS: In TI, regular transfusions are associated with less pronounced cardiac remodeling but increase the risk of MIO. Replacement myocardial fibrosis is a frequent finding associated with cardiac complications.
Up to 1 mg daily. There is no evidence that doses greater than 1 mg/day have greater efficacy than those of 1 mg; additionally, loss of folate in urine becomes roughly logarithmic as the amount administered exceeds 1 mg. 

Each 50, 100, and 200 mg vial of leucovorin calcium for injection when reconstituted with 5, 10, and 20 mL, respectively, of sterile diluent yields a leucovorin concentration of 10 mg per mL. Each 350 mg vial of leucovorin calcium for injection when reconstituted with 17.5 mL of sterile diluent yields a leucovorin concentration of 20 mg per mL. Leucovorin calcium for injection contains no preservative. Reconstitute the lyophilized vial product with Bacteriostatic Water for Injection, USP (benzyl alcohol preserved), or Sterile Water for Injection, USP. When reconstituted with Bacteriostatic Water for Injection, USP, the resulting solution must be used within 7 days. If the product is reconstituted with Sterile Water for Injection, USP, use immediately and discard any unused portion. 

Because of the benzyl alcohol contained in Bacteriostatic Water for Injection, USP, when doses greater than 10 mg/m2 are administered, leucovorin calcium for injection should be reconstituted with Sterile Water for Injection, USP, and used immediately (see WARNINGS). Because of the calcium content of the leucovorin solution, no more than 160 mg of leucovorin should be injected intravenously per minute (16 mL of a 10 mg/mL, or 8 mL of a 20 mg/mL solution per minute). 

Parenteral products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. 

Leucovorin calcium for injection should not be mixed in the same infusion as 5-fluorouracil, since this may lead to the formation of a precipitate.
Chronic prostate inflammation in patients with benign prostate hyperplasia (BPH) correlates with the severity of symptoms. How inflammation contributes to prostate enlargement and/or BPH symptoms and the underlying mechanisms remain unclear. In this study, we utilize a unique transgenic mouse model that mimics chronic non-bacterial prostatitis in men and investigate the impact of inflammation on androgen receptor (AR) in basal prostate stem cells (bPSC) and their differentiation in vivo. We find that inflammation significantly enhances AR levels and activity in bPSC. More importantly, we identify interleukin 1 receptor antagonist (IL-1RA) as a crucial regulator of AR in bPSC during inflammation. IL-1RA is one of the top molecules upregulated by inflammation, and inhibiting IL-1RA reverses the enhanced AR activity in organoids derived from inflamed bPSC. Additionally, IL-1RA appears to activate AR by counteracting IL-1α's inhibitory effect. Furthermore, using a lineage tracing model, we observe that inflammation induces bPSC proliferation and differentiation into luminal cells even under castrate conditions, indicating that AR activation driven by inflammation is sufficient to promote bPSC proliferation and differentiation. Taken together, our study uncovers mechanisms through which inflammation modulates AR signaling in bPSC and induces bPSC luminal differentiation that may contribute to prostate hyperplasia.
Temporal lobe epilepsy is a common form of epilepsy that is often associated with hippocampal sclerosis (HS). Although HS is commonly considered a binary assessment in radiologic evaluation, it is known that histopathologic changes occur in distinct clusters. Some subtypes of HS only affect certain subfields, resulting in minimal changes to the overall volume of the hippocampus. This is likely a major reason why whole hippocampal volumetrics have underperformed versus expert readers in the diagnosis of HS. With recent advancements in MRI technology, it is now possible to characterize the substructure of the hippocampus more accurately. However, this is not consistently addressed in radiographic evaluations. The histologic subtype of HS is critical for prognosis and treatment decision-making, necessitating improved radiologic classification of HS. The International League Against Epilepsy (ILAE) has issued a consensus classification scheme for subtyping HS histopathologic changes. This review aims to explore how the ILAE subtypes of HS correlate with radiographic findings, introduce a grading system that integrates radiologic and pathologic reporting in HS, and outline an approach to detecting HS subtypes by using MRI. This framework will not only benefit current clinical evaluations, but also enhance future studies involving high-resolution MRI in temporal lobe epilepsy.
An example peritoneal dialysis system is disclosed. The example peritoneal dialysis system includes an automated peritoneal dialysis (“APD”) machine comprising a pumping mechanism and a peritoneal dialysis fluid heater. The example peritoneal dialysis system also includes a disposable set comprising a disposable cassette operable with the pumping mechanism and a heater bag operable with the heater. The example peritoneal dialysis system additionally includes a conductivity sensor positioned and arranged to provide feedback to the APD machine. The example APD machine is configured to mix a peritoneal dialysis fluid for treatment in the heater bag using a plurality of peritoneal dialysis constituent fluids. In addition, the example APD machine is configured to use feedback from the conductivity sensor to evaluate the mixed peritoneal dialysis fluid for treatment.
The invention relates to new application of neuropeptide: orexin A, in particular to new application of orexin to preparing the drugs against cerebral ischemia-reperfusion injury. The invention is characterized by application of orexin A to preparing the drugs for treating cerebral ischemia. The orexin A is prepared into 30mu g-1000mu g of lyophilized powder. When being used, the lyophilized powder is diluted with PBS or pure water to serve as injection or spray. The orexin A is prepared into 300mu g of lyophilized powder. The invention provides application of orexin A to preparing the drugs for treating cerebral ischemia.
The present medical support system produces situation reports about a patient experiencing a medical event. A wearable medical device worn by the patient when in use, gathers patient data from which situation reports are generated. The support system uses situation factors associated with the medical event to generate from the patient data, situation reports including situation information associated with the medical event. A rapid communication connection is established between the device of the support person and the wearable medical device and/or remote computing device(s), such as a BLE connection, QR code, etc. The support system presents the adapted situation reports from the remote computing device to various support persons assisting the patient during a critical time for care. In some implementations, the situation reports are generated on the fly according to levels of expertise of the support person.
Severe drug-induced liver injury with fatal outcome occurred in STIVARGA-treated patients in clinical trials. In most cases, liver dysfunction occurred within the first 2 months of therapy and was characterized by a hepatocellular pattern of injury. 

In the CORRECT study, fatal hepatic failure occurred in 1.6% of patients in the regorafenib arm and in 0.4% of patients in the placebo arm. In the GRID study, fatal hepatic failure occurred in 0.8% of patients in the regorafenib arm. In the RESORCE study, there was no increase in the incidence of fatal hepatic failure as compared to placebo [see Adverse Reactions (6.1)]. 

Obtain liver function tests (ALT, AST, and bilirubin) before initiation of STIVARGA and monitor at least every two weeks during the first 2 months of treatment. Thereafter, monitor monthly or more frequently as clinically indicated. Monitor liver function tests weekly in patients experiencing elevated liver function tests until improvement to less than 3 times the ULN or baseline.

Temporarily hold and then reduce or permanently discontinue STIVARGA depending on the severity and persistence of hepatotoxicity as manifested by elevated liver function tests or hepatocellular necrosis [see Dosage and Administration (2.2) and Use in Specific Populations (8.6)].
The infused lipid particles provided by PERIKABIVEN are expected to be cleared from the blood stream in a manner thought to be comparable to the clearing of chylomicrons. In healthy volunteers, the maximum clearance rate of the triglycerides after fasting overnight has been found to be 3.8 ± 1.5g/kg per 24 hours. 

Both elimination and oxidation rates are dependent on the patient's clinical condition; elimination is faster and utilization is increased in postoperative patients, in sepsis, burns and trauma, while patients with renal impairment and hypertriglyceridemia may show lower utilization of exogenous lipid emulsions. Due to differences in elimination, patients with these conditions should be closely monitored during PERIKABIVEN administration [see Warnings and Precautions (5.10, 5.12)]. 

The disposition of infused amino acids, dextrose and electrolytes are essentially the same as those supplied by ordinary food. 

A clinical study in healthy volunteers employing high intravenous doses (80 mmol) of either sodium glycerophosphate used in PERIKABIVEN or reference, inorganic sodium phosphate demonstrated that both compounds resulted in comparable serum inorganic phosphate concentrations after a single intravenous dose. Changes from baseline in the serum levels of sodium, potassium and total calcium were comparable across the two phosphate sources in this study.
The present invention relates to an information processing apparatus and method for managing an examination room. To facilitate management of the whole of one or a plurality of examination rooms. An information processing device (5) manages an examination room in which an analysis device for analyzing a sample is installed. An information processing device (5) is provided with: a communication unit (50) that communicates with a terminal (6) operable by a user; and a control unit (51) that controls the display of the terminal (6) via the communication unit (50). A control unit (51) displays a screen including an index indicating the state of the whole of one or more examination rooms on a terminal (6) on the basis of information collected from a plurality of analysis devices (10) set in the one or more examination rooms or devices (11, 12, 13, 14) associated with the analysis devices (10). The control unit (51) divides the selected index into a plurality of categories and displays the categories on the terminal (6) in accordance with the index selected by the user and displayed on the screen.
During the fixation of the stereotactic frame, a single hypnosis session is performed by a certified senior anesthesiologist. Blood pressure, heart rate and respiratory rate are continuously monitored by the mean of a regular scope. Pain perceived during and after the procedure is quantifies by the mean of the Visual Analogue Scale (VAS) questionnaire. An open, standardized question will be asked to participants concerning feelings and thoughts about the frame fixation. Answers will be audio recorded. A standardized perceived distress questionnaire (PDI-13) will be performed.
Participants are invited to use a version of the app for 21 days. Participants receive only the non-core intervention components and do not attend coaching calls.
FIELD: medicine, biochemistry. SUBSTANCE: invention relates to preparing glycoprotein antigen from B. pseudomallei. Method involves the use of two-day culture of virulent strain B. pseudomallei (Australian serovara) grown on cellophane film placed on solid nutrient medium surface. Culture is inactivated with acetone and an aqueous-salt extract is prepared by homogenization of 2% microbe cells suspension under mild conditions. Then homogeneity is subjected for successive fractionation by gel-filtration on carrier "Toyopearl HW-60", pH 7.2, and ion-exchange chromatography on DEAE-Sephadex A-50, pH 7.7, using 0.05 M tris-HCl as a buffer solution containing sodium chloride at concentration 0-1 M. Isolated glycoprotein consists of protein and carbohydrate at ratio 1:6 that shows homogeneity at immunoelectrophoresis assay. Significant protective effect is obtained after preliminary immunization of white mice with glycoprotein infected with virulent strains of Ps. pseudomallei. Preparation can be used for melioidosis vaccine making. EFFECT: improved method of preparing. 3 tbl
Ultrasonographic characteristics of skeletal muscles are related to their health status and functional capacity, but they still provide limited information on muscle composition during the inflammatory process. It has been demonstrated that an alteration in muscle composition or structure can have disparate effects on different ranges of ultrasonogram pixel intensities. Therefore, monitoring specific clusters or bands of pixel intensity values could help detect echotextural changes in skeletal muscles associated with neurogenic inflammation. Here we compare two methods of ultrasonographic image analysis, namely, the echointensity (EI) segmentation approach (EI banding method) and detection of selective pixel intensity ranges correlated with the expression of inflammatory regulators using an in-house developed computer algorithm (r-Algo). This study utilized an experimental model of neurogenic inflammation in segmentally linked myotomes (i.e., rectus femoris (RF) muscle) of rats subjected to lumbar facet injury. Our results show that there were no significant differences in RF echotextural variables for different EI bands (with 50- or 25-pixel intervals) between surgery and sham-operated rats, and no significant correlations among individual EI band pixel characteristics and protein expression of inflammatory regulators studied. However, mean numerical pixel values for the pixel intensity ranges identified with the proprietary r-Algo computer program correlated with protein expression of ERK1/2 and substance P (both 86-101-pixel ranges) and CaMKII (86-103-pixel range) in RF, and were greater (p < 0.05) in surgery rats compared with their sham-operated counterparts. Our findings indicate that computer-aided identification of specific pixel intensity ranges was critical for ultrasonographic detection of changes in the expression of inflammatory mediators in neurosegmentally-linked skeletal muscles of rats after facet injury.
BACKGROUND: Syncope can be the presenting symptom of Pulmonary Embolism (PE). It is not known wether using a standardized algorithm to rule-out PE in all patients with syncope admitted to the Emergency Departments (ED) is of value or can lead to overdiagnosis and overtreatment.
METHODS: We tested if simple anamnestic and clinical parameters could be used as a rule to identify patients with syncope and PE in a multicenter observational study. The rule's sensitivity was tested on a cohort of patients that presented to the ED for syncopal episodes caused by PE. The clinical impact of the rule was assessed on a population of consecutive patients admitted for syncope in the ED.
RESULTS: Patients were considered rule-positive in the presence of any of the following: hypotension, tachycardia, peripheral oxygen saturation ≤ 93 % (SpO2), chest pain, dyspnea, recent history of prolonged bed rest, clinical signs of deep vein thrombosis, history of previous venous thrombo-embolism and active neoplastic disease. The sensitivity of the rule was 90.3 % (95 % CI: 74.3 % to 98.0 %). The application of the rule to a population of 217 patients with syncope would have led to a 70 % reduction in the number of subjects needing additional diagnostic tests to exclude PE.
CONCLUSIONS: Most patients with syncope due to PE present with anamnestic and clinical features indicative of PE diagnosis. A clinical decision rule can be used to identify patients who would benefit from further diagnostic tests to exclude PE, while reducing unnecessary exams that could lead to over-testing and over-diagnosis.
The invention discloses an insertable medical device for delivering one or more pro-healing agents to a site of deployment of a stent in a blood vessel. The surface of the insertable medical device is coated with nano-carriers that include the one or more pro-healing agents encapsulated with one or more biological agents. The nano-carriers are released when the insertable medical device is expanded at the site. The nano-carriers thus released penetrate tissues at the site resulting in dissolution of the one or more biological agents. Thereafter, the one or more pro-healing agents are released from the nano-carriers at the site. Thus, an in-tissue release of the one or more pro-healing agents at the site is achieved thereby improving endothealization, extracellular matrix formation and healing at the site post deployment of the stent in the blood vessel.
Depression is a mood disorder characterized by abnormal thoughts. The pathophysiology of depression is related to the deficiency of serotonin (5HT), which is derived from tryptophan (Trp). Mitochondrial dysfunction, oxidative stress, and neuroinflammation are involved in the pathogenesis of depression. Notably, the renin-angiotensin system (RAS) is involved in the pathogenesis of depression, and different findings revealed that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) may be effective in depression. However, the underlying mechanism for the role of dysregulated brain RAS-induced depression remains speculative. Therefore, this review aimed to revise the conceivable role of ACEIs and ARBs and how these agents ameliorate the pathophysiology of depression. Dysregulation of brain RAS triggers the development and progression of depression through the reduction of brain 5HT and expression of brain-derived neurotrophic factor (BDNF) and the induction of mitochondrial dysfunction, oxidative stress, and neuroinflammation. Therefore, inhibition of central classical RAS by ARBS and ACEIs and activation of non-classical RAS prevent the development of depression by regulating 5HT, BDNF, mitochondrial dysfunction, oxidative stress, and neuroinflammation.